Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Outcomes of Monthly vs As Needed Ranibizumab in Neovascular AMD
NCT00764738Phase 3Completed
- Sponsor
- Retina Macula Institute
- Start
- Oct 2008
- Primary completion
- Nov 2011
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised trial of ranibizumab in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Retina Macula Institute. Primary endpoints: Multifocal Electroretinography N1-P1 Amplitude at 1 year and Microperimetry Mean Sensitivity at 1 year. Started Oct 2008; status: completed.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00764738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00764738.